Manipulation of indoleamine 2,3 dioxygenase; a novel therapeutic target for treatment of diseases

Expert Opinion on Therapeutic Targets

Volumn 13, Issue 8, 2009, Pages 987-1012

  Tan, P H ^a,b   Bharath, A K ^b  

^a UNIVERSITY OF OXFORD   (United Kingdom)

^b WEXHAM PARK HOSPITAL   (United Kingdom)

Author keywords

Autoimmune diseases and asthma; Chronic infection; IDO; Transplant rejection; Tumour tolerance

Indexed keywords

1,4 NAPHTHOQUINONE DERIVATIVE; ACETYLSALICYLIC ACID; ASPARGINE GLYCINE ARGININE PEPTIDE; BETA (3 BENZO[B]THIENYL)DEXTRO ALANINE; BETA (3 BENZOFURANYL)DEXTRO ALANINE; CANCER VACCINE; CYCLOOXYGENASE 2 INHIBITOR; GAMMA INTERFERON; GLUCOCORTICOID INDUCED TUMOR NECROSIS FACTOR RECEPTOR; IMIDAZOLE DERIVATIVE; INDOLEAMINE 2,3 DIOXYGENASE; KYNURENINE; MENADIONE; N METHYLTRYPTOPHAN; NICOTINAMIDE ADENINE DINUCLEOTIDE; NONSTEROID ANTIINFLAMMATORY AGENT; PEPTIDE; SMALL INTERFERING RNA; TRANILAST; TRYPTOPHAN; TUMOR NECROSIS FACTOR ALPHA; UNCLASSIFIED DRUG;

ALLERGIC ENCEPHALOMYELITIS; ASTHMA; AUTOIMMUNE DISEASE; BACTERIAL STRAIN; CANCER THERAPY; CATABOLISM; DENDRITIC CELL; DISEASE ACTIVITY; DRUG TARGETING; ENZYME ACTIVITY; ENZYME INHIBITION; GRAFT REJECTION; HUMAN; IMMUNOHISTOCHEMISTRY; INFECTION; LUNG CANCER; NATURAL KILLER CELL; NONHUMAN; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; REVIEW; T LYMPHOCYTE; TRYPTOPHAN METABOLISM; UTERINE CERVIX CANCER;

ANIMALS; DOWN-REGULATION; DRUG DELIVERY SYSTEMS; ENZYME ACTIVATION; ENZYME INHIBITORS; HUMANS; INDOLEAMINE-PYRROLE 2,3,-DIOXYGENASE; UP-REGULATION;

EID: 69149084827     PISSN: 14728222     EISSN: None     Source Type: Journal    
DOI: 10.1517/14728220903018940     Document Type: Review

References (245)

1. Munn DH, Zhou M, Attwood JT, et al. Prevention of allogeneic fetal rejection by tryptophan catabolism. Science 1998;281(5380):1191-1193 (Pubitemid 28406294)
2. Beutelspacher SC, Tan PH, Mcclure MO, et al. Expression of indoleamine 2,3-dioxygenase (IDO) by endothelial cells: implications for the control of alloresponses. Am J Transplant 2006;6(6):1320-1330
3. Munn DH, Sharma MD, Lee JR, et al. Potential regulatory function of human dendritic cells expressing indoleamine 2,3-dioxygenase. Science 2002;297(5588):1867-1870
4. Mackenzie CR, Hadding U, Daubener W. Interferon-γ-induced activation of indoleamine 2,3-dioxygenase in cord blood monocyte-derived macrophages inhibits the growth of group B streptococci. J Infect Dis 1998;178(3):875-878 (Pubitemid 28397242)
5. Leonhardt RM, Lee SJ, Kavathas PB, Cresswell P. Severe tryptophan starvation blocks onset of conventional persistence and reduces reactivation of Chlamydia trachomatis. Infect Immun 2007;75(11):5105-5117 (Pubitemid 350033597)
6. Mellor AL, Munn DH. IDO expression by dendritic cells: tolerance and tryptophan catabolism. Nat Rev Immunol 2004;4(10):762-774
7. Puccetti P, Fallarino F. Generation of T cell regulatory activity by plasmacytoid dendritic cells and tryptophan catabolism. Blood Cells Mol Dis 2008;40(1):101-105 (Pubitemid 350192308)
8. Fallarino F, Grohmann U, You S, et al. The combined effects of tryptophan starvation and tryptophan catabolites down-regulate T cell receptor ζ-chain and induce a regulatory phenotype in naive T cells. J Immunol 2006;176(11):6752-6761 (Pubitemid 43787857)
9. Chen W, Liang X, Peterson AJ, et al. The indoleamine 2,3-dioxygenase pathway is essential for human plasmacytoid dendritic cell-induced adaptive T regulatory cell generation. J Immunol 2008;181(8):5396-5404
10. Romani L, Fallarino F, De Luca A, et al. Defective tryptophan catabolism underlies inflammation in mouse chronic granulomatous disease. Nature 2008;451(7175):211-215
11. Dai H, Dai Z. The role of tryptophan catabolism in acquisition and effector function of memory T cells. Curr Opin Organ Transpl 2008;13(1):31-35
12. Liu Z, Dai H, Wan N, et al. Suppression of memory CD8 T cell generation and function by tryptophan catabolism. J Immunol 2007;178(7):4260-4266 (Pubitemid 46492376)
13. Puccetti P. On watching the watchers: IDO and type I/II IFN. Eur J Immunol 2007;37(4):876-879 (Pubitemid 46925324)
14. + dendritic cells. Eur J Immunol 2007;37(4):1064-1071
15. Lopez AS, Alegre E, Lemaoult J, et al. Regulatory role of tryptophan degradation pathway in HLA-G expression by human monocyte-derived dendritic cells. Mol Immunol 2006;43(14):2151-2160 (Pubitemid 43831200)
16. Lopez AS, Alegre E, Diaz-Lagares A, et al. Effect of 3-hydroxyanthranilic acid in the immunosuppressive molecules indoleamine dioxygenase and HLA-G in macrophages. Immunol Lett 2008;117(1):91-95
17. Belladonna ML, Grohmann U, Guidetti P, et al. Kynurenine pathway enzymes in dendritic cells initiate tolerogenesis in the absence of functional IDO. J Immunol 2006;177(1):130-137 (Pubitemid 43939124)
18. Grohmann U, Volpi C, Fallarino F, et al. Reverse signaling through GITR ligand enables dexamethasone to activate IDO in allergy. Nat Med 2007;13(5):579-586 (Pubitemid 46828479)
19. Adikari SB, Lian H, Link H, et al. Interferon-γ-modified dendritic cells suppress B cell function and ameliorate the development of experimental autoimmune myasthenia gravis. Clin Exp Immunol 2004;138(2):230-236 (Pubitemid 39472438)
20. Frumento G, Rotondo R, Tonetti M, et al. Tryptophan-derived catabolites are responsible for inhibition of T and natural killer cell proliferation induced by indoleamine 2,3-dioxygenase. J Exp Med 2002;196(4):459-468 (Pubitemid 34940985)
21. Terness P, Bauer TM, Rose L, et al. Inhibition of allogeneic T cell proliferation by indoleamine 2,3-dioxygenase-expressing dendritic cells: mediation of suppression by tryptophan metabolites. J Exp Med 2002;196(4):447-457 (Pubitemid 34940984)
22. Hayashi T, Mo JH, Gong X, et al. 3-Hydroxyanthranilic acid inhibits PDK1 activation and suppresses experimental asthma by inducing T cell apoptosis. Proc Natl Acad Sci USA 2007;104(47):18619-18624 (Pubitemid 350210746)
23. Taher YA, Piavaux BJ, Gras R, et al. Indoleamine 2,3-dioxygenase- dependent tryptophan metabolites contribute to tolerance induction during allergen immunotherapy in a mouse model. J Allergy Clin Immunol 2008;121(4):983-91, e982
24. Romani L, Zelante T, De Luca A, et al. IL-17 and therapeutic kynurenines in pathogenic inflammation to fungi. J Immunol 2008;180(8):5157-5162
25. De Luca A, Montagnoli C, Zelante T et al. Functional yet balanced reactivity to Candida albicans requires TRIF, MyD88, and IDO-dependent inhibition of Rorc. J Immunol 2007;179(9):5999-6008
26. Della Chiesa M, Carlomagno S, Frumento G, et al. The tryptophan catabolite L-kynurenine inhibits the surface expression of NKp46- and NKG2D-activating receptors and regulates NK-cell function. Blood 2006;108(13):4118-4125 (Pubitemid 44913283)
27. Molano A, Illarionov PA, Besra GS, et al. Modulation of invariant natural killer T cell cytokine responses by indoleamine 2,3-dioxygenase. Immunol Lett 2008;117(1):81-90
28. Romani L, Puccetti P. Protective tolerance to fungi: the role of IL-10 and tryptophan catabolism. Trends Microbiol 2006;14(4):183-189
29. Mellor AL, Munn DH. Tryptophan catabolism and T-cell tolerance: immunosuppression by starvation? Immunol Today 1999;20(10):469-473
30. Belladonna ML, Orabona C, Grohmann U, Puccetti P. TGF-β and kynurenines as the key to infectious tolerance. Trends Mol Med 2009;15(2):41-49
31. Puccetti P, Grohmann U. IDO and regulatory T cells: a role for reverse signalling and non-canonical NF-κB activation. Nat Rev Immunol 2007;7(10):817-823 (Pubitemid 47480306)
32. + regulatory T cells. J Immunol 2005;174(9):5181- 5186
33. Fallarino F, Grohmann U, Vacca C, et al. T cell apoptosis by tryptophan catabolism. Cell Death Differ 2002;9(10):1069-1077
34. Platten M, Ho PP, Youssef S, et al. Treatment of autoimmune neuroinflammation with a synthetic tryptophan metabolite. Science 2005;310(5749):850-855 (Pubitemid 41567343)
35. Tan PH, Lota AS. Interaction of current cancer treatments and the immune system: implications for breast cancer therapeutics. Expert Opin Pharmacother 2008;9(15):2639-2660
36. Muller AJ, Prendergast GC. Marrying immunotherapy with chemotherapy: why say IDO? Cancer Res 2005;65(18):8065-8068
37. Boyland E, Williams DC. The metabolism of tryptophan. 2. The metabolism of tryptophan in patients suffering from cancer of bladder. Biochem J 1959;64:578-584
38. Ozaki Y, Edelstein MP, Duch DS. Induction of indoleamine 2,3-dioxygenase: a mechanism of the antitumor activity of interferon γ. Proc Natl Acad Sci USA 1988;85(4):1242-1246 (Pubitemid 18073985)
39. Carlin JM, Borden EC, Sondel PM, Byrne GI. Interferon-induced indoleamine 2,3-dioxygenase activity in human mononuclear phagocytes. J Leukoc Biol 1989;45(1):29-34
40. Burke F, Knowles RG, East N, Balkwill FR. The role of indoleamine 2,3-dioxygenase in the anti-tumour activity of human interferon-γ in vivo. Int J Cancer 1995;60(1):115-122
41. Schroecksnadel K, Winkler C, Fuith LC, Fuchs D. Tryptophan degradation in patients with gynecological cancer correlates with immune activation. Cancer Lett 2005;223(2):323-329 (Pubitemid 40719630)
42. Uyttenhove C, Pilotte L, Theate I, et al. Evidence for a tumoral immune resistance mechanism based on tryptophan degradation by indoleamine 2,3-dioxygenase. Nat Med 2003;9(10):1269-1274 (Pubitemid 37279849)
43. Denz H, Orth B, Weiss G, et al. Weight loss in patients with hematological neoplasias is associated with immune system stimulation. Clin Investig 1993;71(1):37-41 (Pubitemid 23041973)
44. Giusti RM, Maloney EM, Hanchard B, et al. Differential patterns of serum biomarkers of immune activation in human T-cell lymphotropic virus type I-associated myelopathy/tropical spastic paraparesis, and adult T-cell leukemia/lymphoma. Cancer Epidemiol Biomarkers Prev 1996;5(9):699-704 (Pubitemid 26304644)
45. Okamoto A, Nikaido T, Ochiai K, et al. Indoleamine 2,3-dioxygenase serves as a marker of poor prognosis in gene expression profiles of serous ovarian cancer cells. Clin Cancer Res 2005;11(16):6030-6039 (Pubitemid 41170335)
46. Ino K, Yoshida N, Kajiyama H, et al. Indoleamine 2,3-dioxygenase is a novel prognostic indicator for endometrial cancer. Br J Cancer 2006;95(11):1555-1561 (Pubitemid 44863359)
47. Huang A, Fuchs D, Widner B, et al. Serum tryptophan decrease correlates with immune activation and impaired quality of life in colorectal cancer. Br J Cancer 2002;86(11):1691-1696 (Pubitemid 34712909)
48. Grant RS, Naif H, Espinosa M, Kapoor V. IDO induction in IFN-γ activated astroglia: a role in improving cell viability during oxidative stress. Redox Rep 2000;5(2-3):101-104 (Pubitemid 30487977)
49. Moffett JR, Els T, Espey MG, et al. Quinolinate immunoreactivity in experimental rat brain tumors is present in macrophages but not in astrocytes. Exp Neurol 1997;144(2):287-301 (Pubitemid 27224557)
50. Moffett JR, Namboodiri MA. Tryptophan and the immune response. Immunol Cell Biol 2003;81(4):247-265
51. Sakamuro D, Elliott KJ, Wechsler-Reya R, Prendergast GC. BIN1 is a novel MYC-interacting protein with features of a tumour suppressor. Nat Genet 1996;14(1):69-77 (Pubitemid 26301549)
52. Peter BJ, Kent HM, Mills IG, et al. BAR domains as sensors of membrane curvature: the amphiphysin BAR structure. Science 2004;303(5657):495-499
53. Miaczynska M, Christoforidis S, Giner A, et al. APPL proteins link Rab5 to nuclear signal transduction via an endosomal compartment. Cell 2004;116(3):445-456 (Pubitemid 38366320)
54. Ge K, Duhadaway J, Sakamuro D, et al. Losses of the tumor suppressor BIN1 in breast carcinoma are frequent and reflect deficits in programmed cell death capacity. Int J Cancer 2000;85(3):376-383 (Pubitemid 30030412)
55. Ge K, Duhadaway J, Du W, et al. Mechanism for elimination of a tumor suppressor: aberrant splicing of a brain-specific exon causes loss of function of Bin1 in melanoma. Proc Natl Acad Sci USA 1999;96(17):9689-9694 (Pubitemid 29398793)
56. Tajiri T, Liu X, Thompson PM, et al. Expression of a MYCN-interacting isoform of the tumor suppressor BIN1 is reduced in neuroblastomas with unfavorable biological features. Clin Cancer Res 2003;9(9):3345-3355 (Pubitemid 37082729)
57. Muller AJ, Duhadaway JB, Donover PS, et al. Inhibition of indoleamine 2,3-dioxygenase, an immunoregulatory target of the cancer suppression gene Bin1, potentiates cancer chemotherapy. Nat Med 2005;11(3):312-319
58. Pfefferkorn ER. Interferon γ blocks the growth of Toxoplasma gondii in human fibroblasts by inducing the host cells to degrade tryptophan. Proc Natl Acad Sci USA 1984;81(3):908-912
59. Brown RR, Ozaki Y, Datta SP, et al. Implications of interferon-induced tryptophan catabolism in cancer, auto-immune diseases and AIDS. Adv Exp Med Biol 1991;294:425-435
60. Yoshida R, Hayaishi O. Induction of pulmonary indoleamine 2,3-dioxygenase by intraperitoneal injection of bacterial lipopolysaccharide. Proc Natl Acad Sci USA 1978;75(8):3998-4000 (Pubitemid 8399859)
61. Yoshida R, Imanishi J, Oku T, et al. Induction of pulmonary indoleamine 2,3-dioxygenase by interferon. Proc Natl Acad Sci USA 1981;78(1):129-132 (Pubitemid 11131252)
62. Schroten H, Spors B, Hucke C, et al. Potential role of human brain microvascular endothelial cells in the pathogenesis of brain abscess: inhibition of Staphylococcus aureus by activation of indoleamine 2,3-dioxygenase. Neuropediatrics 2001;32(4):206-210 (Pubitemid 32895903)
63. Friberg M, Jennings R, Alsarraj M, et al. Indoleamine 2,3-dioxygenase contributes to tumor cell evasion of T cell- mediated rejection. Int J Cancer 2002;101(2):151-155 (Pubitemid 34970907)
64. Sarsero JP, Merino E, Yanofsky C. A Bacillus subtilis operon containing genes of unknown function senses tRNATrp charging and regulates expression of the genes of tryptophan biosynthesis. Proc Natl Acad Sci USA 2000;97(6):2656-2661 (Pubitemid 30159227)
65. Xie G, Bonner CA, Jensen RA. Dynamic diversity of the tryptophan pathway in chlamydiae: reductive evolution and a novel operon for tryptophan recapture. Genome Biol 2002;3(9):research0051
66. Fleckner J, Martensen PM, Tolstrup AB, et al. Differential regulation of the human, interferon inducible tryptophanyl-tRNA synthetase by various cytokines in cell lines. Cytokine 1995;7(1):70-77
67. Sanni LA, Thomas SR, Tattam BN, et al. Dramatic changes in oxidative tryptophan metabolism along the kynurenine pathway in experimental cerebral and noncerebral malaria. Am J Pathol 1998;152(2):611-619
68. Guillonneau C, Mintern JD, Hubert FX, et al. Combined NKT cell activation and influenza virus vaccination boosts memory CTL generation and protective immunity. Proc Natl Acad Sci USA 2009;106(16):6724-6729
69. Baggiolini M, Wymann MP. Turning on the respiratory burst. Trends Biochem Sci 1990;15(2):69-72
70. Sun Y. Indoleamine 2,3-dioxygenase-a new antioxidant enzyme. Mater Med Pol 1989;21(3):244-250
71. Hayaishi O. Utilization of superoxide anion by indoleamine oxygenase-catalyzed tryptophan and indoleamine oxidation. Adv Exp Med Biol 1996;398:285-289 (Pubitemid 126426242)
72. Satoh MS, Poirier GG, Lindahl T. Dual function for poly(ADP-ribose) synthesis in response to DNA strand breakage. Biochemistry 1994;33(23):7099-7106 (Pubitemid 24208746)
73. Bieganowska K, Hollsberg P, Buckle GJ, et al. Direct analysis of viral-specific CD8+ T cells with soluble HLA-A2/ Tax11-19 tetramer complexes in patients with human T cell lymphotropic virus-associated myelopathy. J Immunol 1999;162(3):1765-1771 (Pubitemid 29307056)
74. Moffett JR, Espey MG, Namboodiri MA. Antibodies to quinolinic acid and the determination of its cellular distribution within the rat immune system. Cell Tissue Res 1994;278(3):461-469
75. Moffett JR, Blinder KL, Venkateshan CN, Namboodiri MA. Differential effects of kynurenine and tryptophan treatment on quinolinate immunoreactivity in rat lymphoid and non-lymphoid organs. Cell Tissue Res 1998;293(3):525-534
76. Heyliger SO, Mazzio EA, Soliman KF. The anti-inflammatory effects of quinolinic acid in the rat. Life Sci 1999;64(14):1177-1187 (Pubitemid 29156865)
77. Refaeli Y, Van Parijs L, Alexander SI, Abbas AK. Interferon γ is required for activation-induced death of T lymphocytes. J Exp Med 2002;196(7):999-1005
78. Tan PH, Beutelspacher SC, Xue SA, et al. Modulation of human dendritic-cell function following transduction with viral vectors: implications for gene therapy. Blood 2005;105(10):3824-3832
79. Jonuleit H, Tuting T, Steitz J, et al. Efficient transduction of mature CD83+ dendritic cells using recombinant adenovirus suppressed T cell stimulatory capacity. Gene Ther 2000;7(3):249-254 (Pubitemid 30113774)
80. Tetsutani K, To H, Torii M, et al. Malaria parasite induces tryptophan-related immune suppression in mice. Parasitology 2007;134(Pt 7):923-930 (Pubitemid 46933275)
81. Bourreau E, Ronet C, Darcissac E, et al. Intralesional Treg suppressive function during human acute and chronic cutaneous leishmaniasis due to Leishmania guyanensis. Infect Immun 2009;77(4):1465-1474
82. Orabona C, Pallotta MT, Volpi C, et al. SOCS3 drives proteasomal degradation of indoleamine 2,3-dioxygenase (IDO) and antagonizes IDO-dependent tolerogenesis. Proc Natl Acad Sci USA 2008;105(52):20828-20833
83. Huengsberg M, Winer JB, Gompels M, et al. Serum kynurenine-to-tryptophan ratio increases with progressive disease in HIV-infected patients. Clin Chem 1998;44(4):858-862 (Pubitemid 28176030)
84. Look MP, Altfeld M, Kreuzer KA, et al. Parallel decrease in neurotoxin quinolinic acid and soluble tumor necrosis factor receptor p75 in serum during highly active antiretroviral therapy of HIV type 1 disease. AIDS Res Hum Retroviruses 2000;16(13):1215-1221 (Pubitemid 30679927)
85. Gisslen M, Larsson M, Norkrans G, et al. Tryptophan concentrations increase in cerebrospinal fluid and blood after zidovudine treatment in patients with HIV type 1 infection. AIDS Res Hum Retroviruses 1994;10(8):947-951 (Pubitemid 24279165)
86. Fuchs D, Moller AA, Reibnegger G, et al. Increased endogenous interferon-gamma and neopterin correlate with increased degradation of tryptophan in human immunodeficiency virus type 1 infection. Immunol Lett 1991;28(3):207-211
87. Zangerle R, Widner B, Quirchmair G, et al. Effective antiretroviral therapy reduces degradation of tryptophan in patients with HIV-1 infection. Clin Immunol 2002;104(3):242-247 (Pubitemid 35191100)
88. Chen YB, Li SD, He YP, et al. Immunosuppressive effect of IDO on T cells in patients with chronic hepatitis B. Hepatol Res 2009;39(5):463-468
89. Cady SG, Sono M. 1-Methyl- DL -tryptophan, β-(3-benzofuranyl)-DL- alanine (the oxygen analog of tryptophan), and β-[3-benzo(b) thienyl]-DL-alanine (the sulfur analog of tryptophan) are competitive inhibitors for indoleamine 2,3-dioxygenase. Arch Biochem Biophys 1991;291(2):326-333
90. Mellor AL, Baban B, Chandler P, et al. Cutting edge: induced indoleamine 2,3 dioxygenase expression in dendritic cell subsets suppresses T cell clonal expansion. J Immunol 2003;171(4):1652-1655 (Pubitemid 36966447)
91. Gurtner GJ, Newberry RD, Schloemann SR, et al. Inhibition of indoleamine 2,3-dioxygenase augments trinitrobenzene sulfonic acid colitis in mice. Gastroenterology 2003;125(6):1762-1773
92. Munn DH, Mellor AL. IDO and tolerance to tumors. Trends Mol Med 2004;10(1):15-18
93. Munn DH, Mellor AL. Indoleamine 2,3-dioxygenase and tumor-induced tolerance. J Clin Invest 2007;117(5):1147-1154
94. Schroecksnadel K, Winkler C, Wirleitner B, et al. Aspirin down-regulates tryptophan degradation in stimulated human peripheral blood mononuclear cells in vitro. Clin Exp Immunol 2005;140(1):41-45 (Pubitemid 40461071)
95. Winkler C, Wirleitner B, Schroecksnadel K, et al. St. John's wort (Hypericum perforatum) counteracts cytokine-induced tryptophan catabolism in vitro. Biol Chem 2004;385(12):1197-1202
96. Winkler C, Wirleitner B, Schroecksnadel K, et al. In vitro effects of two extracts and two pure alkaloid preparations of Uncaria tomentosa on peripheral blood mononuclear cells. Planta Med 2004;70(3):205-210
97. Girgin G, Baydar T, Ledochowski M, et al. Immunomodulatory effects of Turkish propolis: changes in neopterin release and tryptophan degradation. Immunobiology 2009;214(2):129-134
98. Jeong YI, Kim SW, Jung ID, et al. Curcumin suppresses the induction of indoleamine 2,3-dioxygenase by blocking the Janus-activated kinase-protein kinase Cδ-STAT1 signaling pathway in interferon-γ-stimulated murine dendritic cells. J Biol Chem 2009;284(6):3700-3708
99. Nikoo S, Bozorgmehr M, Namdar Ahmadabad, et al. The 14kDa protein molecule isolated from garlic suppresses indoleamine 2, 3-dioxygenase metabolites in mononuclear cells in vitro. Iran J Allergy Asthma Immunol 2008;7(4):203-208
100. Volgraf M, Lumb JP, Brastianos HC, et al. Biomimetic synthesis of the IDO inhibitors exiguamine A and B. Nat Chem Biol 2008;4(9):535-537
101. Kumar S, Malachowski WP, Duhadaway JB, et al. Indoleamine 2,3-dioxygenase is the anticancer target for a novel series of potent naphthoquinone-based inhibitors. J Med Chem 2008;51(6):1706-1718
102. Kumar S, Jaller D, Patel B, et al. Structure based development of phenylimidazole-derived inhibitors of indoleamine 2,3-dioxygenase. J Med Chem 2008;51(16):4968-4977
103. Yen MC, Lin CC, Chen YL, et al. A novel cancer therapy by skin delivery of indoleamine 2,3-dioxygenase siRNA. Clin Cancer Res 2009;15(2):641-649
104. Lake RA, Robinson BW. Immunotherapy and chemotherapy-a practical partnership. Nat Rev Cancer 2005;5(5):397-405
105. Polak L, Turk JL. Reversal of immunological tolerance by cyclophosphamide through inhibition of suppressor cell activity. Nature 1974;249(458):654-656
106. Machiels JP, Reilly RT, Emens LA, et al. Cyclophosphamide, doxorubicin, and paclitaxel enhance the antitumor immune response of granulocyte/macrophage- colony stimulating factor-secreting whole-cell vaccines in HER-2/neu tolerized mice. Cancer Res 2001;61(9):3689-3697
107. Emens LA, Machiels JP, Reilly RT, Jaffee EM. Chemotherapy: friend or foe to cancer vaccines? Curr Opin Mol Ther 2001;3(1):77-84
108. Rad AN, Pollara G, Sohaib SM, et al. The differential influence of allogeneic tumor cell death via DNA damage on dendritic cell maturation and antigen presentation. Cancer Res 2003;63(16):5143-5150 (Pubitemid 37022656)
109. Ossina NK, Cannas A, Powers VC, et al. Interferon-γ modulates a p53-independent apoptotic pathway and apoptosis-related gene expression. J Biol Chem 1997;272(26):16351-16357 (Pubitemid 27276459)
110. Muller AJ, Sharma MD, Chandler PR, et al. Chronic inflammation that facilitates tumor progression creates local immune suppression by inducing indoleamine 2,3 dioxygenase. Proc Natl Acad Sci USA 2008;105(44):17073-17078
111. Belladonna ML, Volpi C, Bianchi R, et al. Cutting edge: Autocrine TGF-β sustains default tolerogenesis by IDO-competent dendritic cells. J Immunol 2008;181(8):5194-5198
112. Huang AY, Golumbek P, Ahmadzadeh M, et al. Role of bone marrow-derived cells in presenting MHC class I-restricted tumor antigens. Science 1994;264(5161):961-965 (Pubitemid 24196166)
113. + T cells. J Exp Med 2003;197(8):985-995
114. + CTL to cause tumor eradication. J Immunol 2004;173(11):6753-6759
115. Nowak AK, Lake RA, Marzo AL, et al. Induction of tumor cell apoptosis in vivo increases tumor antigen cross-presentation, cross-priming rather than cross-tolerizing host tumor-specific CD8 T cells. J Immunol 2003;170(10):4905- 4913
116. Hargadon KM, Brinkman CC, Sheasley-O'Neill SL, et al. Incomplete differentiation of antigen-specific CD8 T cells in tumor-draining lymph nodes. J Immunol 2006;177(9):6081-6090
117. Kraal G, Samsom JN, Mebius RE. The importance of regional lymph nodes for mucosal tolerance. Immunol Rev 2006;213:119-130 (Pubitemid 44401497)
118. Munn DH, Mellor AL. The tumor-draining lymph node as an immune-privileged site. Immunol Rev 2006;213:146-158
119. Cochran AJ, Huang RR, Lee J, et al. Tumour-induced immune modulation of sentinel lymph nodes. Nat Rev Immunol 2006;6(9):659-670 (Pubitemid 44298215)
120. Von Bergwelt-Baildon MS, Popov A, Saric T et al. CD25 and indoleamine 2,3-dioxygenase are up-regulated by prostaglandin E2 and expressed by tumor-associated dendritic cells in vivo: additional mechanisms of T-cell inhibition. Blood 2006;108(1):228-237 (Pubitemid 43990633)
121. Lee JR, Dalton RR, Messina JL, et al. Pattern of recruitment of immunoregulatory antigen-presenting cells in malignant melanoma. Lab Invest 2003;83(10):1457-1466
122. Lee JH, Torisu-Itakara H, Cochran AJ, et al. Quantitative analysis of melanoma-induced cytokine-mediated immunosuppression in melanoma sentinel nodes. Clin Cancer Res 2005;11(1):107-112
123. Munn DH, Sharma MD, Hou D, et al. Expression of indoleamine 2,3-dioxygenase by plasmacytoid dendritic cells in tumor-draining lymph nodes. J Clin Invest 2004;114(2):280-290 (Pubitemid 39071633)
124. Munn DH, Sharma MD, Baban B, et al. GCN2 kinase in T cells mediates proliferative arrest and anergy induction in response to indoleamine 2,3-dioxygenase. Immunity 2005;22(5):633-642 (Pubitemid 40719198)
125. Agaugue S, Perrin-Cocon L, Coutant F, et al. 1-Methyl-tryptophan can interfere with TLR signaling in dendritic cells independently of IDO activity. J Immunol 2006;177(4):2061-2071 (Pubitemid 44200963)
126. Lob S, Konigsrainer A, Schafer R, et al. Levo- but not dextro-1-methyl tryptophan abrogates the IDO activity of human dendritic cells. Blood 2008;111(4):2152-2154
127. Hou DY, Muller AJ, Sharma MD, et al. Inhibition of indoleamine 2,3-dioxygenase in dendritic cells by stereoisomers of 1-methyl-tryptophan correlates with antitumor responses. Cancer Res 2007;67(2):792-801
128. MunnDH, Mellor AL, Rossi M, Young JW. Dendritic cells have the option to express IDO-mediated suppression or not. Blood 2005;105(6):2618 (Pubitemid 40387070)
129. Sawitzki B, Kingsley CI, Oliveira V, et al. IFN-γ production by alloantigen-reactive regulatory T cells is important for their regulatory function in vivo. J Exp Med 2005;201(12):1925-1935 (Pubitemid 41002929)
130. + cells modulate pulmonary immune responses by production of indoleamine 2,3-dioxygenase. Am J Respir Cell Mol Biol 2004;30(3):311-318
131. Quan J, Tan PH, Macdonald A, Friend PJ. Manipulation of indoleamine 2,3-dioxygenase (IDO) for clinical transplantation: promises and challenges. Expert Opin Biol Ther 2008;8(11):1705-1719
132. Fallarino F, Orabona C, Vacca C, et al. Ligand and cytokine dependence of the immunosuppressive pathway of tryptophan catabolism in plasmacytoid dendritic cells. Int Immunol 2005;17(11):1429-1438 (Pubitemid 41631319)
133. Grohmann U, Orabona C, Fallarino F, et al. CTLA-4-Ig regulates tryptophan catabolism in vivo. Nat Immunol 2002;3(11):1097-1101 (Pubitemid 35363664)
134. Fallarino F, Grohmann U, Hwang KW, et al. Modulation of tryptophan catabolism by regulatory T cells. Nat Immunol 2003;4(12):1206-1212 (Pubitemid 37547898)
135. Liu H, Liu L, Visner GA. Nonviral gene delivery with indoleamine 2,3-dioxygenase targeting pulmonary endothelium protects against ischemia-reperfusion injury. Am J Transplant 2007;7(10):2291-2300 (Pubitemid 47347865)
136. Sono M, Roach MP, Coulter ED, Dawson JH. Heme-containing oxygenases. Chem Rev 1996;96(7):2841-2888
137. Hirata F, Hayaishi O. Studies on indoleamine 2,3-dioxygenase. I. Superoxide anion as substrate. J Biol Chem 1975;250(15):5960-5966
138. Hayaishi O, Hirata F, Ohnishi T, et al. Indoleamine 2,3-dioxygenase: incorporation of 18O2- and 18O2 into the reaction products. J Biol Chem 1977;252(10):3548-3550
139. Hirata F, Ohnishi T, Hayaishi O. Indoleamine 2,3-dioxygenase. Characterization and properties of enzyme. O2- complex. J Biol Chem 1977;252(13):4637-4642 (Pubitemid 8155985)
140. Sono M, Taniguchi T, Watanabe Y, Hayaishi O. Indoleamine 2,3-dioxygenase. Equilibrium studies of the tryptophan binding to the ferric, ferrous, and CO-bound enzymes. J Biol Chem 1980;255(4):1339-1345
141. Ozaki Y, Reinhard JF Jr, Nichol CA, Duch DS. Cofactor activity of dihydroflavin mononucleotide and tetrahydrobiopterin for murine epididymal indoleamine 2,3-dioxygenase. Biochem Biophys Res Commun 1986;137(3):1106-1111 (Pubitemid 16049406)
142. Ozaki Y, Nichol CA, Duch DS. Utilization of dihydroflavin mononucleotide and superoxide anion for the decyclization of L-tryptophan by murine epididymal indoleamine 2,3-dioxygenase. Arch Biochem Biophys 1987;257(1):207-216 (Pubitemid 17123164)
143. Vottero E, Mitchell DA, Page MJ, et al. Cytochrome b5 is a major reductant in vivo of human indoleamine 2,3-dioxygenase expressed in yeast. FEBS Lett 2006;580(9):2265-2268
144. Maghzal GJ, Thomas SR, Hunt NH, Stocker R. Cytochrome b5, not superoxide anion radical, is a major reductant of indoleamine 2,3-dioxygenase in human cells. J Biol Chem 2008;283(18):12014-12025
145. Brandacher G, Cakar F, Winkler C, et al. Non-invasive monitoring of kidney allograft rejection through IDO metabolism evaluation. Kidney Int 2007;71(1):60-67 (Pubitemid 44967735)
146. Beutelspacher SC, Pillai R, Watson MP, et al. Function of indoleamine 2,3-dioxygenase in corneal allograft rejection and prolongation of allograft survival by over-expression. Eur J Immunol 2006;36(3):690-700
147. Forrest CM, Kennedy A, Stone TW, et al. Kynurenine and neopterin levels in patients with rheumatoid arthritis and osteoporosis during drug treatment. Adv Exp Med Biol 2003;527:287-295 (Pubitemid 38197654)
148. Schroecksnadel K, Kaser S, Ledochowski M, et al. Increased degradation of tryptophan in blood of patients with rheumatoid arthritis. J Rheumatol 2003;30(9):1935-1939 (Pubitemid 37075539)
149. Wolf AM, Wolf D, Rumpold H, et al. Overexpression of indoleamine 2,3-dioxygenase in human inflammatory bowel disease. Clin Immunol 2004;113(1):47-55 (Pubitemid 39468267)
150. Kwidzinski E, Bunse J, Aktas O, et al. Indolamine 2,3-dioxygenase is expressed in the CNS and down-regulates autoimmune inflammation. FASEB J 2005;19(10):1347-1349 (Pubitemid 41113745)
151. Hayashi T, Beck L, Rossetto C, et al. Inhibition of experimental asthma by indoleamine 2,3-dioxygenase. J Clin Invest 2004;114(2):270-279 (Pubitemid 39071632)
152. Nakahara M, Nagayama Y, Saitoh O, et al. Expression of immunoregulatory molecules by thyrocytes protects nonobese diabetic H2h4 mice from developing autoimmune thyroiditis. Endocrinology 2009;150(3):1545-1551
153. Maneechotesuwan K, Wamanuttajinda V, Kasetsinsombat K, et al. Der p 1 suppresses indoleamine 2, 3-dioxygenase in dendritic cells from house dust mite-sensitive patients with asthma. J Allergy Clin Immunol 2009;123(1):239-48
154. Wang J, Simonavicius N, Wu X, et al. Kynurenic acid as a ligand for orphan G protein-coupled receptor GPR35. J Biol Chem 2006;281(31):22021-22028 (Pubitemid 44181906)
155. Bianco NR, Kim SH, Ruffner MA, Robbins PD. Therapeutic effect of exosomes from indoleamine 2,3-dioxygenase-positive dendritic cells in collagen-induced arthritis and delayed-type hypersensitivity disease models. Arthritis Rheum 2009;60(2):380-389
156. Segal BH, Romani L, Puccetti P. Chronic granulomatous disease. Cell Mol Life Sci 2009;66(4):553-558
157. Fallarino F, Vacca C, Orabona C, et al. Functional expression of indoleamine 2,3-dioxygenase by murine CD8α + dendritic cells. Int Immunol 2002;14(1):65-68
158. + CD45RClow T cells, IFN-γ, and indoleamine 2,3-dioxygenase. J Clin Invest 2007;117(4):1096-1106
159. Degauque N, Lair D, Dupont A, et al. Dominant tolerance to kidney allografts induced by anti-donor MHC class II antibodies: cooperation between T and non-T CD103+ cells. J Immunol 2006;176(7):3915-3922 (Pubitemid 44264368)
160. Fallarino F, Asselin-Paturel C, Vacca C, et al. Murine plasmacytoid dendritic cells initiate the immunosuppressive pathway of tryptophan catabolism in response to CD200 receptor engagement. J Immunol 2004;173(6):3748-3754 (Pubitemid 39280736)
161. Tan PH, Beutelspacher SC, Wang YH, et al. Immunolipoplexes: an efficient, nonviral alternative for transfection of human dendritic cells with potential for clinical vaccination. Mol Ther 2005;11(5):790-800
162. Hwu P, Du MX, Lapointe R, et al. Indoleamine 2,3-dioxygenase production by human dendritic cells results in the inhibition of T cell proliferation. J Immunol 2000;164(7):3596-3599 (Pubitemid 30169812)
163. Terness P, Chuang JJ, Bauer T, et al. Regulation of human auto- and alloreactive T cells by indoleamine 2,3-dioxygenase (IDO)-producing dendritic cells: too much ado about IDO? Blood 2005;105(6):2480-2486
164. Pree I, Bigenzahn S, Fuchs D, et al. CTLA4Ig promotes the induction of hematopoietic chimerism and tolerance independently of Indoleamine-2, 3-dioxygenase. Transplantation 2007;83(5):663-667 (Pubitemid 46440260)
165. Orabona C, Puccetti P, Vacca C, et al. Toward the identification of a tolerogenic signature in IDO-competent dendritic cells. Blood 2006;107(7):2846-2854
166. Orabona C, Belladonna ML, Vacca C, et al. Cutting edge: silencing suppressor of cytokine signaling 3 expression in dendritic cells turns CD28-Ig from immune adjuvant to suppressant. J Immunol 2005;174(11):6582-6586 (Pubitemid 40705617)
167. Sharma MD, Baban B, Chandler P, et al. Plasmacytoid dendritic cells from mouse tumor-draining lymph nodes directly activate mature Tregs via indoleamine 2,3-dioxygenase. J Clin Invest 2007;117(9):2570-2582 (Pubitemid 47494358)
168. Thomas SR, Terentis AC, Cai H, et al. Post-translational regulation of human indoleamine 2,3-dioxygenase activity by nitric oxide. J Biol Chem 2007;282(33):23778-23787 (Pubitemid 47328013)
169. Tan PH, Xue SA, Manunta M, et al. Effect of vectors on human endothelial cell signal transduction: implications for cardiovascular gene therapy. Arterioscler Thromb Vasc Biol 2006;26(3):462-467
170. Couzin J, Kaiser J. Gene therapy. As Gelsinger case ends, gene therapy suffers another blow. Science 2005;307(5712):1028
171. Carmen IH. A death in the laboratory: the politics of the Gelsinger aftermath. Mol Ther 2001;3(4):425-428
172. Tan PH, Janes SE, Handa AI, Friend PJ: More trouble ahead; is gene therapy coming of age? Expert Opin Biol Ther 2008;8(5):561-567
173. TanPH, Tan PL, George AJ, Chan CL. Gene therapy for transplantation with viral vectors - how much of the promise has been realized? Expert Opin Biol Ther 2006;6(8):759-772
174. Hacein-Bey-Abina S, Von Kalle C, Schmidt M, et al. A serious adverse event after successful gene therapy for X-linked severe combined immunodeficiency. N Engl J Med 2003;348(3):255-256 (Pubitemid 36077924)
175. Laurence JM, Wang C, Zheng M, et al. Overexpression of indoleamine dioxygenase in rat liver allografts using a high-efficiency adeno-associated virus vector does not prevent acute rejection. Liver Transpl 2009;15(2):233-241
176. Rayner SA, Larkin DF, George AJ. TNF receptor secretion after ex vivo adenoviral gene transfer to cornea and effect on in vivo graft survival. Invest Ophthalmol Vis Sci 2001;42(7):1568-1573
177. HIV Vaccine Trial Network: November 2007 HVTN Conference Presentations. Available from: http://www.hvtn.org/science/1107.html [Last access 13 May 2008]
178. Tan PH, Chan CL, George AJ. Strategies to improve non-viral vectors - potential applications in clinical transplantation. Expert Opin Biol Ther 2006;6(6):619-630
179. Orabona C, Grohmann U, Belladonna ML, et al. CD28 induces immunostimulatory signals in dendritic cells via CD80 and CD86. Nat Immunol 2004;5(11):1134-1142 (Pubitemid 39549627)
180. Guillemin GJ, Smythe G, Takikawa O, Brew BJ. Expression of indoleamine 2,3-dioxygenase and production of quinolinic acid by human microglia, astrocytes, and neurons. Glia 2005;49(1):15-23 (Pubitemid 40023649)
181. Clinical trial: 1-methyl-D-tryptophan in treating patients with relapsed or refractory solid tumors. Available from: http://clinicaltrials.gov/show/ NCT00788086 (2008) [Last accessed 13 May 2009]
182. Clinical trial: A phase 1 study of 1-methyl-D-tryptophan in patients with advanced malignancies. Available from: http://clinicaltrials.gov/ct2/show/ NCT00617422 (2009) [Last accessed 13 May 2009]
183. Katz JB, Muller AJ, Prendergast GC. Indoleamine 2,3-dioxygenase in T-cell tolerance and tumoral immune escape. Immunol Rev 2008;222:206-221
184. Popov A, Schultze JL. IDO-expressing regulatory dendritic cells in cancer and chronic infection. J Mol Med 2008;86(2):145-160 (Pubitemid 351172124)
185. Mellor AL, Munn DH. Creating immune privilege: active local suppression that benefits friends, but protects foes. Nat Rev Immunol 2008;8(1):74-80
186. Popov A, Abdullah Z, Wickenhauser C, et al. Indoleamine 2,3-dioxygenase-expressing dendritic cells form suppurative granulomas following Listeria monocytogenes infection. J Clin Invest 2006;116(12):3160-3170 (Pubitemid 44878630)
187. Gasparri AM, Jachetti E, Colombo B, et al. Critical role of indoleamine 2,3-dioxygenase in tumor resistance to repeated treatments with targeted IFNγ. Mol Cancer Ther 2008;7(12):3859-3866
188. Hoshi M, Ito H, Fujigaki H, et al. Indoleamine 2,3-dioxygenase is highly expressed in human adult T-cell leukemia/lymphoma and chemotherapy changes tryptophan catabolism in serum and reduced activity. Leuk Res 2009;33(1):39-45
189. Corm S, Berthon C, Imbenotte M, et al. Indoleamine 2,3-dioxygenase activity of acute myeloid leukemia cells can be measured from patients' sera by HPLC and is inducible by IFN-γ. Leuk Res 2009;33(3):490-494
190. + T regulatory cells. Blood 2007;109(7):2871-2877
191. Tang XQ, Zhao ZG, Wang HX, et al. Indoleamine 2, 3-dioxygenase activity in acute myeloid leukemia cells contributing to tumor immune escape. Zhongguo Shi Yan Xue Ye Xue Za Zhi 2006;14(3):539-542
192. Riesenberg R, Weiler C, Spring O, et al. Expression of indoleamine 2,3-dioxygenase in tumor endothelial cells correlates with long-term survival of patients with renal cell carcinoma. Clin Cancer Res 2007;13(23):6993-7002 (Pubitemid 350276880)
193. Feder-Mengus C, Wyler S, Hudolin T, et al. High expression of indoleamine 2,3-dioxygenase gene in prostate cancer. Eur J Cancer 2008;44(15):2266-2275
194. Kai S, Goto S, Tahara K, et al. Inhibition of indoleamine 2,3-dioxygenase suppresses NK cell activity and accelerates tumor growth. J Exp Ther Oncol 2003;3(6):336-345 (Pubitemid 38056112)
195. Liebau C, Baltzer Aw, Schmidt S, et al: Interleukin-12 and interleukin-18 induce indoleamine 2,3-dioxygenase (IDO) activity in human osteosarcoma cell lines independently from interferon-gamma. Anticancer Res 2002;22(2A):931-936 (Pubitemid 34475252)
196. Zheng X, Koropatnick J, Li M, et al. Reinstalling antitumor immunity by inhibiting tumor-derived immunosuppressive molecule IDO through RNA interference. J Immunol 2006;177(8):5639-5646 (Pubitemid 44527639)
197. Beutelspacher SC, Serbecic N. Potential endogenous immunological self-protection of uveal melanoma by indoleamine 2,3-dioxygenase. Klin Monatsbl Augenheilkd 2008;225(8):703-707
198. Chen PW, Mellon JK, Mayhew E, et al. Uveal melanoma expression of indoleamine 2,3-deoxygenase: establishment of an immune privileged environment by tryptophan depletion. Exp Eye Res 2007;85(5):617-625 (Pubitemid 47633574)
199. Polak ME, Borthwick NJ, Gabriel FG, et al. Mechanisms of local immunosuppression in cutaneous melanoma. Br J Cancer 2007;96(12):1879-1887
200. Kobayashi A, Weinberg V, Darragh T, Smith-mccune K. Evolving immunosuppressive microenvironment during human cervical carcinogenesis. Mucosal Immunol 2008;1(5):412-420
201. Nakamura T, Shima T, Saeki A, et al. Expression of indoleamine 2, 3-dioxygenase and the recruitment of Foxp3-expressing regulatory T cells in the development and progression of uterine cervical cancer. Cancer Sci 2007;98(6):874-881 (Pubitemid 46691826)
202. Sedlmayr P, Semlitsch M, Gebru G, et al. Expression of indoleamine 2,3-dioxygenase in carcinoma of human endometrium and uterine cervix. Adv Exp Med Biol 2003;527:91-95 (Pubitemid 38197632)
203. Yoshida N, Ino K, Ishida Y, et al. Overexpression of indoleamine 2,3-dioxygenase in human endometrial carcinoma cells induces rapid tumor growth in a mouse xenograft model. Clin Cancer Res 2008;14(22):7251-7259
204. Ino K, Yamamoto E, Shibata K, et al. Inverse correlation between tumoral indoleamine 2,3-dioxygenase expression and tumor-infiltrating lymphocytes in endometrial cancer: its association with disease progression and survival. Clin Cancer Res 2008;14(8):2310-2317 (Pubitemid 351551062)
205. Brandacher G, Perathoner A, Ladurner R, et al. Prognostic value of indoleamine 2,3-dioxygenase expression in colorectal cancer: effect on tumor-infiltrating T cells. Clin Cancer Res 2006;12(4):1144-1151 (Pubitemid 43342502)
206. Tinder TL, Subramani DB, Basu GD, et al. MUC1 enhances tumor progression and contributes toward immunosuppression in a mouse model of spontaneous pancreatic adenocarcinoma. J Immunol 2008;181(5):3116-3125
207. Witkiewicz A, Williams TK, Cozzitorto J, et al. Expression of indoleamine 2,3-dioxygenase in metastatic pancreatic ductal adenocarcinoma recruits regulatory T cells to avoid immune detection. J Am Coll Surg 2008;206(5):849-54; discussion 854-1846
208. Ishio T, Goto S, Tahara K, et al. Immunoactivative role of indoleamine 2,3-dioxygenase in human hepatocellular carcinoma. J Gastroenterol Hepatol 2004;19(3):319-326 (Pubitemid 38338742)
209. Pan K, Wang H, Chen MS, et al: Expression and prognosis role of indoleamine 2,3-dioxygenase in hepatocellular carcinoma. J Cancer Res Clin Oncol 2008;134(11):1247-1253
210. Basu GD, Tinder TL, Bradley JM, et al. Cyclooxygenase-2 inhibitor enhances the efficacy of a breast cancer vaccine: role of IDO. J Immunol 2006;177(4):2391-2402
211. Karanikas V, Zamanakou M, Kerenidi T, et al. Indoleamine 2,3-dioxygenase (IDO) expression in lung cancer. Cancer Biol Ther 2007;6(8):1258-1262 (Pubitemid 351590380)
212. Hucke C, Mackenzie CR, Adjogble KD, et al. Nitric oxide-mediated regulation of gamma interferon-induced bacteriostasis: inhibition and degradation of human indoleamine 2,3-dioxygenase. Infect Immun 2004;72(5):2723-2730 (Pubitemid 38542399)
213. Mackenzie CR, Worku D, Daubener W. Regulation of IDO-mediated bacteriostasis in macrophages: role of antibiotics and anti-inflammatory agents. Adv Exp Med Biol 2003;527:67-76 (Pubitemid 38197629)
214. Heseler K, Spekker K, Schmidt SK, et al. Antimicrobial and immunoregulatory effects mediated by human lung cells: role of IFN-γ-induced tryptophan degradation. FEMS Immunol Med Microbiol 2008;52(2):273-281 (Pubitemid 351248434)
215. Murr C, Gerlach D, Widner B, et al. Neopterin production and tryptophan degradation in humans infected by Streptococcus pyogenes. Med Microbiol Immunol 2001;189(3):161-163 (Pubitemid 33726402)
216. Pantoja LG, Miller RD, Ramirez JA, et al. Inhibition of Chlamydia pneumoniae replication in human aortic smooth muscle cells by gamma interferon-induced indoleamine 2, 3-dioxygenase activity. Infect Immun 2000;68(11):6478-6481
217. Sakash JB, Byrne GI, Lichtman A, Libby P. Cytokines induce indoleamine 2,3-dioxygenase expression in human atheroma-asociated cells: implications for persistent Chlamydophila pneumoniae infection. Infect Immun 2002;70(7):3959-3961 (Pubitemid 34666040)
218. Rottenberg ME, Gigliotti Rothfuchs A, Gigliotti D, et al. Regulation and role of IFN-γ in the innate resistance to infection with Chlamydia pneumoniae. J Immunol 2000;164(9):4812-4818 (Pubitemid 30238084)
219. Carlin JM, Ozaki Y, Byrne GIR, et al. Interferons and indoleamine 2,3-dioxygenase: role in antimicrobial and antitumor effects. Experientia 1989;45(6):535-541 (Pubitemid 19151363)
220. Mackler AM, Barber EM, Takikawa O, Pollard JW. Indoleamine 2,3-dioxygenase is regulated by IFN-γ in the mouse placenta during Listeria monocytogenes infection. J Immunol 2003;170(2):823-830 (Pubitemid 36070534)
221. De Sousa R, Ismail N, Nobrega SD et al. Intralesional expression of mRNA of interferon-γ, tumor necrosis factor-a, interleukin-10, nitric oxide synthase, indoleamine-2,3-dioxygenase, and RANTES is a major immune effector in Mediterranean spotted fever rickettsiosis. J Infect Dis 2007;196(5):770-781 (Pubitemid 47293861)
222. Moreau M, Lestage J, Verrier D, et al. Bacille Calmette-Guerin inoculation induces chronic activation of peripheral and brain indoleamine 2,3-dioxygenase in mice. J Infect Dis 2005;192(3):537-544 (Pubitemid 41023135)
223. Greub G, Desnues B, Raoult D, Mege JL. Lack of microbicidal response in human macrophages infected with Parachlamydia acanthamoebae. Microbes Infect 2005;7(4):714-719 (Pubitemid 40720427)
224. Yoshida R, Urade Y, Tokuda M, Hayaishi O. Induction of indoleamine 2,3-dioxygenase in mouse lung during virus infection. Proc Natl Acad Sci USA 1979;76(8):4084-4086 (Pubitemid 9249028)
225. Brown BD, Sitia G, Annoni A, et al. In vivo administration of lentiviral vectors triggers a type I interferon response that restricts hepatocyte gene transfer and promotes vector clearance. Blood 2007;109(7):2797-2805
226. Potula R, Poluektova L, Knipe B, et al. Inhibition of indoleamine 2,3-dioxygenase (IDO) enhances elimination of virus-infected macrophages in animal model of HIV-1 encephalitis. Blood 2005;106(7):2382-2390 (Pubitemid 41510811)
227. Burudi EM, Marcondes MC, Watry DD, et al. Regulation of indoleamine 2,3-dioxygenase expression in simian immunodeficiency virus-infected monkey brains. J Virol 2002;76(23):12233-12241
228. Depboylu C, Reinhart TA, Takikawa O, et al. Brain virus burden and indoleamine-2,3-dioxygenase expression during lentiviral infection of rhesus monkey are concomitantly lowered by 6-chloro-2′,3′-dideoxyguanosine. Eur J Neurosci 2004;19(11):2997-3005 (Pubitemid 38822590)
229. Obojes K, Andres O, Kim KS, et al. Indoleamine 2,3-dioxygenase mediates cell type-specific anti-measles virus activity of gamma interferon. J Virol 2005;79(12):7768-7776 (Pubitemid 40756810)
230. Bozza S, Fallarino F, Pitzurra L, et al. A crucial role for tryptophan catabolism at the host/Candida albicans interface. J Immunol 2005;174(5):2910-2918 (Pubitemid 40279709)
231. Nagineni CN, Pardhasaradhi K, Martins MC, et al. Mechanisms of interferon-induced inhibition of Toxoplasma gondii replication in human retinal pigment epithelial cells. Infect Immun 1996;64(10):4188-4196 (Pubitemid 26318141)
232. Daubener W, Spors B, Hucke C, et al. Restriction of Toxoplasma gondii growth in human brain microvascular endothelial cells by activation of indoleamine 2,3-dioxygenase. Infect Immun 2001;69(10):6527-6531 (Pubitemid 32885221)
233. Fujigaki S, Saito K, Takemura M, et al. L-tryptophan-L-kynurenine pathway metabolism accelerated by Toxoplasma gondii infection is abolished in gamma interferon-gene-deficient mice: cross-regulation between inducible nitric oxide synthase and indoleamine-2, 3-dioxygenase. Infect Immun 2002;70(2):779-786 (Pubitemid 34083840)
234. Hansen AM, Driussi C, Turner V, et al. Tissue distribution of indoleamine 2,3-dioxygenase in normal and malaria-infected tissue. Redox Rep 2000;5(2-3):112-115 (Pubitemid 30487979)
235. Hansen AM, Ball HJ, Mitchell AJ, et al. Increased expression of indoleamine 2,3-dioxygenase in murine malaria infection is predominantly localised to the vascular endothelium. Int J Parasitol 2004;34(12):1309-1319
236. Bertera S, Alexander AM, Crawford ML, et al. Gene combination transfer to block autoimmune damage in transplanted islets of Langerhans. Exp Diabesity Res 2004;5(3):201-210 (Pubitemid 39386568)
237. Alexander AM, Crawford M, Bertera S, et al. Indoleamine 2,3-dioxygenase expression in transplanted NOD islets prolongs graft survival after adoptive transfer of diabetogenic splenocytes. Diabetes 2002;51(2):356-365 (Pubitemid 34764790)
238. Jalili RB, Rayat GR, Rajotte RV, Ghahary A. Suppression of islet allogeneic immune response by indoleamine 2, 3 dioxygenase-expressing fibroblasts. J Cell Physiol 2007;213(1):137-143 (Pubitemid 47378801)
239. Haspot F, Seveno C, Dugast AS, et al. Anti-CD28 Antibody-induced kidney allograft tolerance related to tryptophan degradation and TCR Class II B7 regulatory cells. Am J Transplant 2005;5(10):2339-2348
240. Li J, Meinhardt A, Roehrich ME, et al. Indoleamine 2,3-dioxygenase gene transfer prolongs cardiac allograft survival. Am J Physiol Heart Circ Physiol 2007;293(6):H3415-23
241. Pan TL, Lin CL, Chen CL, et al. Identification of the indoleamine 2,3-dioxygenase nucleotide sequence in a rat liver transplant model. Transpl Immunol 2000;8(3):189-194
242. Li Y, Tredget EE, Ghaffari A, et al. Local expression of indoleamine 2,3-dioxygenase protects engraftment of xenogeneic skin substitute. J Invest Dermatol 2006;126(1):128-136 (Pubitemid 43336104)
243. Bauer TM, Jiga LP, Chuang JJ, et al. Studying the immunosuppressive role of indoleamine 2,3-dioxygenase: tryptophan metabolites suppress rat allogeneic T-cell responses in vitro and in vivo. Transpl Int 2005;18(1):95-100
244. Liu H, Liu L, Fletcher BS, Visner GA. Novel action of indoleamine 2,3-dioxygenase attenuating acute lung allograft injury. Am J Respir Crit Care Med 2006;173(5):566-572
245. Liu H, Liu L, Fletcher BS, Visner GA. Sleeping Beauty-based gene therapy with indoleamine 2,3-dioxygenase inhibits lung allograft fibrosis. Faseb J 2006;20(13):2384-2386